Nilotinib shows prolonged intracellular accumulation upon pulse-exposure: a novel mechanism for induction of apoptosis in CML cells

Intracellular Retention of ABL Kinase Inhibitors Determines Commitment to Apoptosis in CML Cells

(2012) Daniel B. Lipka et al.   PLoS One

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis

(2009) J. L. Snead et al.   BLOOD

Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties

(2009) C Hegedűs et al.   BRITISH JOURNAL OF PHARMACOLOGY

Short-term intense Bcr–Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL+ cells

(2009) D K Hiwase et al.   LEUKEMIA

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

(2008) R. A. Larson et al.   BLOOD

Transient Potent BCR-ABL Inhibition Is Sufficient to Commit Chronic Myeloid Leukemia Cells Irreversibly to Apoptosis

(2008) Neil P. Shah et al.   CANCER CELL